Clinical Trial

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 22, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.
Trial Details
NCT Number NCT06326736
Lead Sponsor Jinling Hospital, China
Collaborators: Jiangsu Synthgene Biotechnology Co.Ltd.
Conditions Pancreatic Cancer
Enrollment 12 participants
Start Date 2024-04
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-03-22